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Abstract
Background: For cases of severe traumatic brain injury, during primary operation, neurosurgeons usually face a
dilemma of whether or not to remove the bone flap after mass lesion evacuation. Decompressive craniectomy,
which involves expansion of fixed cranial cavity, is used to treat intra-operative brain swelling and post-operative
malignant intracranial hypertension. However, due to indefinite indication, the decision to perform this procedure
heavily relies on personal experiences. In addition, decompressive craniectomy is associated with various
complications, and the procedure lacks strong evidence of better outcomes. In the present study, we designed a
prospective, randomized, controlled trial to clarify the effect of decompressive craniectomy in severe traumatic
brain injury patients with mass lesions.
Methods: PRECIS is a prospective, randomized, assessor-blind, single center clinical trial. In this trial, 336 patients with
traumatic mass lesions will be randomly allocated to a therapeutic decompressive craniectomy group or a prophylactic
decompressive craniectomy group. In the therapeutic decompressive craniectomy group, the bone flap will be removed
or replaced depending on the emergence of brain swelling. In the prophylactic decompressive craniectomy group, the
bone flap will be removed after mass lesion evacuation. A stepwise management of intracranial pressure will be provided
according to the Brain Trauma Foundation guidelines. Salvage decompressive craniectomy will be performed for
craniotomy patients once there is evidence of imaging deterioration and post-operative malignant intracranial
hypertension. Participants will be assessed at 1, 6 and 12 months after randomization. The primary endpoint is favorable
outcome according to the Extended Glasgow Outcome Score (5–8) at 12 months. The secondary endpoints include
quality of life measured by EQ-5D, mortality, complications, intracranial pressure and cerebral perfusion pressure control
and incidence of salvage craniectomy in craniotomy patients at each investigation time point.
Discussion: This study will provide evidence to optimize primary decompressive craniectomy application and assess
outcomes and risks for mass lesions in severe traumatic brain injury.
Trial registration: ISRCTN20139421
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Background
Severe traumatic brain injury (STBI) is a major cause of
death in young adults in developed countries [1]. In
China, due to increasing traffic accidents, head injury
occurs above 1 per 1000 [2]. The mortality of STBI is
between 30 % and 50 %. According to a report from the
Asian Development Bank, the annual economic loss
from traffic accidents is equivalent to 1 %–3 % of China’s
gross national product [3]. Considering the per capita in-
come and limited medical resources, rational and effect-
ive treatment of STBI is of important economic and
social significance.
Most STBI patients with intracranial hypertension attri-
bute to mass lesions, such as contusion and subdural
haematoma (SDH) [4, 5]. Severe primary injury and exas-
perate condition necessitate emergent surgical interven-
tion. The available type of operation is either craniotomy
or decompressive craniectomy (DC).
Craniotomy is the most widely used surgical treatment
for STBI. This operation keeps the skull intact but the
risk of post-operative refractory hypertension remains;
thus, requires a salvage surgery. DC is another broadly
used operation for STBI rescue, which involves the re-
moval of the frontal, parietal and temporal skull to ex-
pand fixed cranial cavity. Some studies indicated that
DC could effectively alleviate refractory intracranial
hypertension [6–10]. However, using DC to treat STBI
has been controversial since the 1970s [11, 12]. The
focus of debate resides in whether DC would be able to
improve the prognosis of patients. Current guidelines
only suggest performing set the role of DC as a ‘surgical
choice’ [5, 13].
Some studies which suggesting primary DC pro-
posed that early aggressive intervention could mitigate
the secondary damages of increased intracranial cere-
bral pressure (ICP) [10, 14–18]. In Europe, a retro-
spective study of 729 patients revealed that one-third
of patients with STBI who received emergency sur-
gery still needed DC even after haematoma evacu-
ation [4]. Others who regarded DC as a second-tier
salvage surgery considered that the long-term, frus-
trating recovery increased the uncertainty of DC [19].
Moreover, the complications remain perplex to sur-
geons [20, 21]. From the early stage of hemorrhagic
progression to the late of cerebrospinal fluid distur-
bances, all these pathophysiologic changes would
negatively impact the outcome of treatment [21–23].
Some authors pointed out that DC rests on the pur-
pose of life-saving but costs severe disability in return
[24, 25].
Except for fulminant intra-operative swelling, when
surgeons take the risk of post-operative refractory hyper-
tension into account, the decision of surgical option
heavily relies on personal experiences. Thus, with the
resurgence of DC, demands for compelling evidence re-
garding the use of DC in clinical practice have gathered
momentum.
There are a few randomized controlled trials that have
studied the use of DC for STBI. The results from com-
pleted trials cannot be generalized for solving the above
questions [26]. DECRA study enrolled 155 cases of trau-
matic diffusion injury and the results suggested that DC
did not show superiority over the best medical treatments
[8]. Some commentators pointed out that the high cross-
over of patients from medical group to DC group in the
DECRA could influence the outcomes [27]. Another not-
able trial is the RESCUE-ICP, which has collected data
from 400 cases [28]. RESCUE-ICP permits craniotomy for
mass lesion evacuation but excludes primary DC using.
The results of this study remain to be concluded.
RESCUE-ASDH, an ongoing trial, projects to compare
primary DC and craniotomy in STBI patients with mass
lesions [29].
However, it is common that the brain swells beyond
the border of the skull window after mass lesion
evacuation. Randomizing patients with brain swelling
to craniotomy would impair patient's benefit. In con-
trast, screening out these patients would decrease
study validity because intra-operative brain swelling is
exactly indication for DC. In our hospital, primary
DC is only selected for fulminant brain swelling,
which we call therapeutic DC. The prophase study
demonstrated that 54 % of patients reached a favor-
able outcome at 12 months after receiving therapeutic
DC [30]. Even for some patients with fixed and di-
lated pupils, the bone flap could still be replaced. We
also found there might be some predictive values of
initial ICP for the risk of post-operative refractory
intracranial hypertension [31]. All of these results
need careful interpretation and prospective study
confirmation.
Thus, considering the above background, we designed
a clinical trial named prospective, randomized evaluation
of therapeutic decompressive craniectomy in severe
traumatic brain injury with mass lesions (PRECIS).
Methods
Study design
PRECIS is a prospective, randomized, assessor-
blinded, controlled clinical trial designed at the West
China Hospital, Sichuan University (Fig. 1). The
study process will follow the Declaration of Helsinki
[32]. The ethical approval was granted for the proto-
col version 1.2 by the Biological and Medical Ethics
Committee (BMEC) of West China Hospital (No.
2015-17). The trial has been registered in the
Current Controlled Trials (ISRCTN20139421).
Whereas the neurologic status of STBI patients who
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will not be expected to give consent themselves, the
lineal consanguinity or legal surrogate will be fully
informed of the study purpose, procedure, potential
risks and benefits. Before the trial process begins, a
triplicate consent will be signed by a kin or a surrogate. Pa-
tients have the right to withdraw any time during the trial.
The primary hypothesis
Therapeutic DC, which is performed on the basis of emer-
gence of intra-operative brain swelling, results in a better
outcome compared with prophylactic DC for STBI patients
with mass lesions.
The secondary hypothesis
1. Therapeutic DC results in fewer complications and a
better quality of life compared with prophylactic DC
2. The risk of salvage craniectomy for post-operative
refractory hypertension in primary craniotomy pa-
tients can be quantified by clinical features.
Eligibility
Inclusion criteria
1. Between 15 and 65 years old;
2. Glasgow Coma Scale (GCS) ≤ 8;
Fig. 1 Flowchart of PRECIS outline
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3. Presence of high- or mix-density lesion ≥ 25 ml
(contusion, intraparenchymal and SDH);
4. Progressive deterioration of neurological status after
24 h of injury (GCS motor score decreases by 2
points or blunt pupillary response);
Exclusion criteria
1. Bilateral mydriasis of critically endangered status;
2. Cerebellum contusion;
3. Penetrating brain injury;
4. Serious extracranial comorbidites with Abbreviated
Injury Scale (AIS) > 3;
5. Beyond 24 h after injury;
6. Known mental or physical disability which would
confound outcome assessment;
7. Breastfeeding or pregnancy;
8. Definite surgical contraindications;
Interventions
To increase consistency between groups, most proce-
dures are the same between the therapeutic DC
group and the prophylactic DC group, except the
bone flap management. Once the legal surrogate signs
consent and confirms randomization, the intervention
commences. Before the operation, the best medical
treatments will be administered in accordance with
the recommendation of the BTF guidelines [33]. For
obtaining full course (initial, intra-operative and post-
operative) of ICP and CPP variations, ICP monitor
will be placed before the craniotomy and kept at least
5 days after surgery. Given the patients with mass le-
sion often associate with ventricles compression and
midline shift, intraparenchymal ICP monitor will be
preferred. The probe will be properly placed and fixed
in the frontal lobe of lesion side drilling through the
designed craniotomy incision without affecting nor-
mal procedure.
The unilateral trauma craniotomy model will be
adopted, as suggested by Potts et al. [34]. The scalp
flap should locate 1 cm beyond the border of the
skull window. Craniotomy should reach at least 15 ×
12 cm with fully exposed areas, which extended down
to the temporal base and curve round the parietal to
the side of the midline within 2 cm. After mass lesion
evacuation, the dura should be sutured on relaxation
and expansion by the temporal fascia or artificial
dura. Then, for the prophylactic DC group, the bone
flap will be removed. For the therapeutic DC group,
the decision of whether or not to replace the bone
flap will depend on brain swelling. If the brain tissue
protrudes above the base of the temporal skull win-
dow, the bone flap will not be replaced.
General care monitoring is aimed to maintain SaO2 >
95 %, mean systolic blood pressure > 90 mmHg,
temperature < 37 °C and PaCO2 35-40 mmHg. Central
venous catheters will be placed in all patients for volume
monitoring and resuscitation.
As per the BTF guideline, a stepwise approach will be
preferred to regulate ICP management. Maintaining ICP
< 25 mmHg and CPP > 60 mmHg are the target of the
critical care treatment. Conventional therapies include
head elevation (30°), ventilation, sedation, osmotic dehy-
dration, external ventricular drainage and neuromuscular
blockade. The short active propofol (5–100 μg/kg/min)
and fentanyl (25–100 μg/h) are used for sedation. Manni-
tol (1 g/kg) is routine diuretic for osmotherapy. Equios-
molar hypertonic saline (23.4 %, 0.686 ml/kg in bolus) will
be considered in patients with refractory intracranial
hypertension or rebound phenomenon treated by manni-
tol. The short half-life of vecuronium (0.2 mg/kg/h) is se-
lected for neuromuscular paralysis agent. Hyperthermia
(32 °C–34 °C) will be added to the STBI patients when
ICP is refractory even maximal medical treatment.
During critical care, repeated computed tomography
(CT) scan will assess intracranial evolution if ICP >
20 mmHg. For craniotomy patients, salvage DC will be per-
formed when there are deterioration of imaging findings
(midline shift > 5 mm and/or cisternal compression) and
malignant intracranial hypertension (ICP 25–30 mmHg >
1 h or ICP > 30 mmHg, regardless time). For DC patients,
even there is no consensus on the optimal time of cranio-
plasty [35], and systematic review also questioned the defin-
ition of “early” which varies from 1 to 4 months [36, 37], it
is rational to recommend bone flap replacement as early as
2 months after surgery once their performances achieving
the clinical standard.
Scheduled CT scan will be performed at 1, 3, 7, 30 and
180 days after surgery. Additional CT scan will carry out
depending on the condition of patient.
Follow-up and data collection
After randomization, patients will be assessed at 1 week
and 1, 6 and 12 months. Patients who cannot be
followed up at seven days will be assessed upon being
discharged. For upfront exit patients, their surrogates
should mark the previous data whether or not could be
used in study. All patient information and imaging find-
ings will be uploaded to a database using the case report
form (CRF).
The initial data collection will be assessed at the
emergency room by an attending physician. This col-
lection will include baseline status, torso and/or ex-
tremities AIS, trauma severity (GCS, motor score and
pupillary reaction), CT parameters (mass lesion type,
volume of haematoma and midline-shift), time of
injury-to-operation, cause of injury and initial
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laboratory features (arterial blood gas parameters, co-
agulation and platelet count).
The 1-week follow-up will include intra-operative
brain swelling event, salvage craniectomy, laboratory fea-
tures, early complications and ICP and CPP control.
Intra-operative monitoring values will be recorded at the
point of probe fixation, dura incision, dura suture and
scalp closure. Post-operative ICP control will be re-
corded as daily ICP burden (number of hrs/d with ICP >
25 mmHg) and total ICP burden (number of days with
ICP > 25 mmHg), as well as the same method recording
daily and total CPP burden (CPP < 60 mmHg) [38].
At 1, 6 and 12 months follow-up, the independent
blinded assessor will face-to-face evaluate intervention
outcomes, quality of life, late complications and time of
cranioplasty using standard questionnaire. The question-
naire includes the Extended Glasgow Outcome Score
(GOSE), EQ-5D. If the discharged patients cannot attend
scheduled follow-up, especially at time point of 6 or
12 months, the questionnaire will be sent to the docu-
mented permanent address. Only if these methods are
invalid, the surrogate will be investigated to finish the
questionnaire by telephone.
Outcomes
The Primary endpoint is a favorable outcome at
12 months after randomization as measured by GOSE
(5–8). The core secondary endpoint is the quality of life
indicated by EQ-5D. Further secondary endpoints in-
clude mortality and complications at corresponding time
point, ICP and CPP control and incidence of salvage DC
in craniotomy patients.
Statistical analysis
The analysis will be processed on the principle of
intention. Patients who drop out or violate initial distribu-
tion will be considered as the worst outcome. Considering
the probability of craniotomy patients treated by salvage
DC, an as-treated analysis will also be implemented, as
recommended in two-arm clinic trial [39]. Parametric data
will be described by mean and standard deviation. Non-
parametric data will be described by median and quartile.
Categorical data will be presented using number and
percentage.
The primary outcome of the study will be evaluated
using the Pearson chi-square test with unadjusted risk
ratio and 95 % confidence interval. Adjusted analysis of
primary outcome will be assessed using logistic regres-
sion for pre-specified factors and any other covariates
presenting significant difference between the two groups.
The pre-specified subgroups include: age, GCS, pupillary
response, mass lesion type and hypotension. Secondary
outcome including assessment of quality of life, mortal-
ity at 6 and 12 months and incidence of complications
will also be assessed using unadjusted analysis and ad-
justed regression. To investigate the risk factors of post-
operative refractory hypertension (salvage DC),
univariate and multivariate analysis will be used to iden-
tify potential variables of craniotomy patients.
Depending on the results of regression models, the re-
ceiver operating curves will be used to evaluate the dis-
crimination. The Hosmer–Lemeshow test will process
the goodness-of-fit of models [40]. A P value < 0.05 is
considered statistically significant. All statistical analysis
will be computed by SPSS software (version 19.0).
Adverse events (AEs) and Serious adverse events (SAEs)
Both AEs and SAEs will be recorded in CRF. AE is de-
fined as any unintended or unfavorable disease that oc-
curs during the study. AEs include DC related
complications, such as cortical herniation, hemorrhage
evolution, infection, hydrocephalus and subdural
hygroma. SAEs are defined as any of the following:
death, life-threatening events, persistent vegetative state,
requirement of hospitalization and prolonged
hospitalization. Once the attending physicians realize
SAE, it should be reported to the trial management team
(TMT) and BMEC within 24 h. SAEs will be followed up
until the issue is properly resolved.
Sample size
The sample size calculation is on the basis of the variance
of outcomes. The favorable outcome of DC in previous
studies ranged from 30 % to 61 % [9, 15, 41–43]. Some re-
sults may not be applicable because they included patients
with diffusion injury and used DC as a secondary therapy.
When primary DC treated patients for mass lesions, the
favorable outcome of prophylactic DC in 781 patients was
38 % [44–54]. In our centre using therapeutic DC, the fa-
vorable outcome of therapeutic DC was 54 % [30]. After
including a safety margin of 10 % to account for patients
who drop out, we calculate that a sample size of 336 (each
arm 168) will be sufficient to reach a significance level of
5 % (two-side) and a power of 80 %. The sample size will
be re-assessed and adjusted during interim analysis.
Randomization
Computer-based central randomization will allocate treat-
ment with minimizing following covariates: age (<40 or ≥
40 years), GCS (8-6 or 5-3), pupillary response (both react-
ive or one reactive or no reactive), mass lesion type (sub-
dural or intracerebral) and hypotension. A random element
will be introduced to enhance the unpredictability of the
minimization algorithm [55]. Physicians can use telephone
or computer to register and randomize eligible patients.
The patients will be assigned to either the therapeutic DC
group or the prophylactic DC group and will receive a
unique identity number for PRECIS records.
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Blinding
Since the study is conducted at a single center and inter-
ventions probably result in different outcomes and qualities
of life, ‘ideal blinding’ is not realistic in PRECIS. We use an
assessor-blinding method to investigate the study outcome.
The independent assessors (IAs) will not be involved in the
randomization or intervention. IAs will not be able to ob-
tain the distribution information or the specific treatment
procedures using CRF.
Quality control and trial administration
Data safety monitoring board
The independent data safety monitoring board
(DSMB) is established to ensure patient safety and
data confidentiality. The members of DSMB include
neurosurgeons, neurology physicians, ethicists and
biological statisticians. The board members should
have no conflicts of interests concerning the trial.
DSMB is granted the highest authority to access the
database. DSMB will launch interim analyses and
further to recommend to the study group. The
closed part of the interim analysis will be confiden-
tial to TMT and related staff. The recommendations
will only suggest terminating the trial if one branch
is significantly different (i.e. >3 SDs) with respect to
primary endpoints or SAEs
Trial steering team
The trial steering team is responsible for supervising the
overall process of the trial and final decisions following
recommendations from DSMB.
Trial management team
The responsibilities of TMT include trial conception,
intervention design, patient safety, quality assurance,
data analysis and writing. TMT will periodically instruct
each team to conduct coordination meetings. According
to recommendations from the interim analysis, TMT
will re-calculate and adjust the sample size if needed.
Trial executive team
As the main administrators of study implementation,
veteran neurosurgeons constitute the trial executive
team (TET). TET will conduct eligible patient
screening, study interpretation, consent signature,
AEs and SAEs reporting, and the CRFs filling. TET
should also provide specific measures to improve the
unqualified ratio and the timeliness of data submis-
sion following interim analysis.
Trial assistant team
The assistant team is composed of IAs and computer
support group (CSG). Following the principle of blind-
ing, IAs will complete study outcome assessment and
submit to DSMB (owning priority) and TMT. CSG will
perform the online random allocation system, database
establishment and maintenance.
Discussion
The bones of contention regarding the use of DC for pa-
tients with STBI are the treatment outcome and risk pre-
diction. This should be settled through practical and
objective clinical trials. PRECIS is the first, prospective,
randomized trial to evaluate the outcome of therapeutic
DC and prophylactic DC during the primary operation in
STBI patients with mass lesions. Compared with com-
pleted trials and ongoing trials, PRECIS is relevant to the
clinical practice and attentive to full course of core param-
eters variation. Excluding patients with intra-operative
brain swelling could decrease the power of study, and des-
ignating these patients to have either craniotomy or DC
would impair patient's benefit. We also try to identify our
prior hypotheses about the risk of post-operative refrac-
tory intracranial hypertension. By focusing on general pa-
tients with mass lesions, this study wishes to describe the
outcomes and prognosis of such patients following DC.
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